Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 47Brain Neoplasms 8Skin Neoplasms 5Neoplasm Metastasis 5Neoplasms 4Uveal Melanoma 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Skin Diseases 2Glioma 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Eye Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

montanide ISA 51 2Interleukin-2 2binimetinib 1belinostat 1Tramadol 1Surgical Procedures, Operative 1Peptides 1MART-1 Antigen 1MAGEA3 protein, human 1Leuprolide 1Laparotomy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Eye Neoplasms × binimetinib × Dermatologic × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡